Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders

Katherine M. Mackey; Johanna K. Anderson; Beth E. Williams; Rachel M. Ward; Nicholas J. Parr

Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders

Review

Washington (DC): Department of Veterans Affairs (US); 2022 Oct.

VA Evidence-based Synthesis Program Reports.

Authors

Katherine M. Mackey¹, Johanna K. Anderson², Beth E. Williams³, Rachel M. Ward⁴, Nicholas J. Parr⁵

Affiliations

¹ Clinician Investigator, Evidence Synthesis Program (ESP) Coordinating Center, Portland VA Health Care System Portland, OR
² Senior Research Associate, ESP Coordinating Center, Portland VA Health Care System Portland, OR
³ Clinician Investigator, ESP Coordinating Center, Portland VA Health Care System Portland, OR
⁴ Research Assistant, ESP Coordinating Center, Portland VA Health Care System Portland, OR
⁵ Associate Director, ESP Coordinating Center, Portland VA Health Care System Portland, OR

PMID: 36413606
Bookshelf ID: NBK586533

Excerpt

The ESP Coordinating Center (ESP CC) is responding to a request from the VA Office of Research and Development (ORD) and VHA Office of Mental Health and Suicide Prevention (OMHSP) for an Evidence Brief on the use of psychedelic substances for treating mental health and substance use disorders. Findings from this Evidence Brief will be used to inform VA research activities and clinical care in the areas of mental health and substance use disorder treatment.

Publication types

Review